Back to Search
Start Over
Accelerated drug approval: Meeting the ethical yardstick.
- Source :
-
Bioethics [Bioethics] 2023 Sep; Vol. 37 (7), pp. 647-655. Date of Electronic Publication: 2023 Jun 21. - Publication Year :
- 2023
-
Abstract
- Drugs addressing unmet medical needs can change the lives of millions. Developing and validating new drugs can, however, take many years. To streamline the assessment of new drugs, regulatory agencies have long established shortened review pathways. Among these programs, Accelerated Approval (AA) has recently come under scrutiny due to the U.S. Food and Drug Administration's decision to authorize Aducanumab, the first Alzheimer's disease drug. This decision attracted fierce criticism due to the allegedly insufficient evidence about the safety and efficacy of the drug. While considerable scholarly attention has been devoted to this case, the ethical aspects of the AA regulatory pathway have so far remained relatively unexplored. In this paper, we set out to fill this gap. We illustrate six conditions that should be met for AA to be ethically acceptable: moral solicitude, evidence, risk mitigation, impartiality, sustainability, and transparency. We discuss such conditions and suggest practical steps to implement them in regulatory and oversight processes. Taken together, our six conditions represent a benchmark for assessing the ethical validity of AA processes and decisions.<br /> (© 2023 The Authors. Bioethics published by John Wiley & Sons Ltd.)
Details
- Language :
- English
- ISSN :
- 1467-8519
- Volume :
- 37
- Issue :
- 7
- Database :
- MEDLINE
- Journal :
- Bioethics
- Publication Type :
- Academic Journal
- Accession number :
- 37341679
- Full Text :
- https://doi.org/10.1111/bioe.13191